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ABSTRACT 
The cerebral metabolic rate of oxygen (CMRO2) has been shown to be an early indicator 
of hypoxia-ischemia (HI); however, the mechanisms controlling post-HI CMRO2 are not 
clear. One potential mechanism is the activation of the adenosine A1 receptor due to 
increased adenosine concentrations during the insult. The present study investigated if the 
specific adenosine A1 antagonist, DPCPX, would attenuate the typical reduction in 
CMRO2 and electrical cortical activity following HI. Measurements of CMRO2 and 
electrical cortical activity were obtained on piglets by near-infrared spectroscopy (NIRS) 
and amplitude-integrated electroencephalography (aEEG), respectively. The post-HI 
measurements of CMRO2 and mean aEEG background voltage were significantly less 
depressed in piglets treated with DPCPX than controls (p <0.05). The significant 
difference in post-HI CMRO2 and aEEG values between DPCPX-treated animals and 
controls suggests that the release of adenosine during HI leads to depressed cerebral 
energy metabolism due to the inhibition of neuronal activity.  
Keywords: 
Near-infrared spectroscopy, cerebral metabolic rate of oxygen, cerebral blood flow, 
hypoxic-ischemic encephalopathy, neonate, piglets, DPCPX, electroencephalography, 
adenosine, antagonist. 
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CHAPTER 1 
1.1 Hypoxic-Ischemic Encephalopathy 
 Perinatal cerebral hypoxic-ischemic encephalopathy (HIE) is the leading cause 
of brain injury in term newborns [1]. Cerebral HIE is defined as an acute reduction in 
the delivery of oxygen and blood flow to the brain [2]. Approximately 1 out of every 
500 term newborns are diagnosed with HIE and, of those, 15 to 20% will not survive 
past the neonatal period. Of the survivors, up to 25% will have significant 
neurological deficits including cerebral palsy, mental retardation and epilepsy [2, 3]. 
Perinatal HIE is primarily associated with events during labor/delivery such as breech 
extractions, rotational maneuvers, prolonged labor, and acute placental or cord 
disturbances. These events result in a loss of cerebral vascular autoregulation, leading 
to insufficient cerebral blood flow and ultimately brain injury, depending on the 
duration and severity of the ischemic insult [4].  
 The onset of hypoxia ischemia (HI) does not bring forth immediate brain injury, 
rather, there is a delay of approximately 12 to 72 h before any evidence of brain 
injury manifests [5]. The realization of this delay has lead to the idea that early 
interventions (i.e. hypothermia [6]) during this period could improve neurological 
outcome and, consequently, the delay is often termed the “therapeutic window” [4, 7, 
8]. Unfortunately, early detection of brain injury in newborns by clinical signs 
(discussed in the following section) can be subtle or manifest after the therapeutic 
window [7, 9]. 
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 The remaining sections of the chapter will discuss techniques for early detection 
of HI in newborns, the biochemistry of HI in early and late phases after onset, and the 
connection to brain injury. The chapter will then shift focus to discuss near-infrared 
spectroscopy (NIRS) and the techniques developed to measure cerebral blood flow 
(CBF) and the cerebral metabolic rate of oxygen (CMRO2). This section will be 
followed by a review of previous studies investigating post-HI changes in cerebral 
energy metabolism, its relationship to brain injury, and the potential mechanisms 
controlling CMRO2 during the reperfusion phase. The chapter will end with an 
overview of clinical studies of NIRS applied to the newborn, which is the focus of the 
appendix. 
1.2 Early Diagnosis and Prognosis 
 Current methods employed for diagnosis of HIE in newborns are limited due to 
the delicate nature of neonatal neurology/physiology. The most commonly used 
indicator of birth asphyxia is heart rate abnormality. It has been reported that 
abnormal fetal heart rate at birth is well correlated with neurological outcome at 1 
year [10]; however, in other cases abnormal heart rate patterns showed no correlation 
with cognitive functions [11]. This difference supports the idea of a natural resiliency 
in newborns through endogenous protectors (such as oligotrophins) against cell death 
[12]. Other diagnostic techniques for assessing HI include low-extended 
APGAR/SARNAT scores, the need for resuscitation in the delivery room, and 
evidence of severe fetal acidemia [13]. All of these techniques suffer from poor 
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specificity and a more precise method of diagnosis of perinatal HI is needed to avoid 
unnecessary treatment of healthy newborns [14].  
 
1.3 Biochemical Aspects 
 To understand the clinical relevance of HIE, we need to investigate its 
pathophysiology, particularly how it affects cerebral metabolism, hemodynamics, 
biochemistry, and tissue viability. 
1.3.1 During Hypoxia-Ischemia 
 Hypoxia-ischemia is usually initiated by a reduction in oxygen (i.e., hypoxia), 
with the onset of ischemia occurring after the loss of autoregulation (i.e. the inability 
of the cerebral vasculature to maintain adequate CBF during systemic hypotension). 
Because of the lack of sufficient oxygen delivery, HI is typically accompanied by a 
compensatory increase in an oxygen independent energy production via anaerobic 
glycolysis and the consumption of high-energy phosphates, such as phosphocreatine 
(PCr) [15]. However, these alternate energy sources are not sufficient to satisfy 
energy demands, resulting in a depletion of adenosine triphosphate (ATP). 
 Insufficient ATP production will adversely affect many cellular mechanisms. 
Of major importance are those processes responsible for cell integrity/structure by 
controlling proper ion balance, primarily Na+, Cl- and Ca2+. Inadequate energy supply 
results in a large influx of these ions into the cells (efflux of potassium and sodium 
ions, an influx of calcium), leading to cellular edema and lysis. The fraction of cells 
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that will undergo irreversible membrane injury will ultimately depend on the severity 
and duration of HI [8]. In addition, this influx of Ca2+ is believed to initiate other 
mechanisms – in particular, the destruction of mitochondrial integrity leading to the 
formation of radical oxygen species (ROS) [8] – that ultimately leads to further 
cellular damage during the reperfusion phase.  
1.3.2 Reperfusion  
The return of normal blood flow and oxygen levels to the brain triggers 
immediate actions that attempt to restore cellular homeostasis. ATP and PCr levels 
are gradually replenished by the return of oxidative metabolism; however, there is 
evidence that mitochondrial function is impaired following HI. Studies have shown 
that mitochondrial impairment, including depressed respiration, is still occurring 6 h 
after HI [16-18]. One study involving a neonatal rat model demonstrated suppressed 
mitochondrial respiration up to a few days after HI [17].  
Mitochondrial dysfunction is known to play a pivotal role in neuro-
degeneration during the reperfusion phase by initiating and being a target of oxidative 
stress [19, 20]. This effect is greatly exasperated by elevated NO levels, which 
combines with O2- to form the highly toxic agent peroxynitrite and inhibits 
mitochondrial respiration [17, 18]. Despite its short half-life, peroxynitrite is able to 
rapidly diffuse across cell membranes and affect surrounding cells [20]. It also 
inactivates enzymes including mitochondrial ATPase, inhibiting mitochondrial 
electron transport, which leads to cells inability to sustain homeostasis and eventually 
apoptosis [21] (Figure 1). 
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Another major event in the neurotoxic cascade during reperfusion is the 
release of glutamate. Excessive glutamate opens N-methyl-D-aspartate (NMDA) 
receptors causing cells to flood with calcium (Ca2+). Increased Ca2+ activates 
inflammatory mediators, generates reactive oxygen species, and increases neuronal 
and inducible nitric oxide synthase (nNOS/iNOS), all of which lead to protein and 
DNA damage and oxidative degradation of lipids. This begins a chain reaction as 
ROS, lipid degradation and NO all enhance glutamate release, leading to further 
influxes of Ca2+ in a vicious cycle that ultimately leads to mitochondrial cell death 
[22]. The administration of an NMDA receptor antagonist has been shown to improve 
mitochondrial respiration and reduce brain injury [23]. The evidence that 
mitochondrial impairment precedes delayed brain injury suggests that assessing 
mitochondrial function could be used as an early marker of ensuing cellular damage 
[16].  
These damaging pathways set forth a biochemical cascade leading to cell 
death, which usually occurs between 24 and 48 h after HI. Delayed brain injury is 
associated with the onset of secondary energy failure as characterized by a crash in 
high-energy metabolites despite normal levels of arterial oxygen saturation, blood 
pressure and blood glucose [24, 25]. It is also associated with seizure activity and 
inflammatory responses [25]. Ultimately, these events lead to mitochondrial swelling, 
release of pro-apoptotic proteins, and cell death [26].  Since the cerebral metabolic 
rate of oxygen reflects mitochondrial energy production, it could be used to detect 
compromised brain function before the onset of secondary energy failure. The 
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following section will discuss techniques for detecting altered cerebral energy 
metabolism during the critical early reperfusion phase.  
 
Figure 1.1- Pathways associated with cell death in hypoxia ischaemia reperfusion 
[8] 
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1.4 Current Techniques for Detecting Compromised Brain Function 
Evidence of impaired cerebral energy metabolism following HI has been 
reported in studies using magnetic resonance spectroscopy (MRS) and 
electroencephalography (EEG) [27, 28]. With MRS, an increase in lactate 
concentration during early reperfusion correlates with insult severity [29-31], 
presumably indicating increased anaerobic metabolism. However, the early lactate 
peak is transient and has been found to suffer from poor specificity [31]. Magnetic 
resonance spectroscopy has also been used to confirm the causal relationship between 
impaired oxidative metabolism and delayed brain injury, as evident by the 
progressive decline in high-energy phosphates and the concurrent increase in lactate 
[15, 24, 32]. However, these changes are not observed until late in the reperfusion 
period – i.e., after the therapeutic window. A practical limitation with using MRS for 
diagnosis of HIE is the need to transport the newborn to the imaging suite, which may 
not be feasible depending on the condition of the patient. 
Amplitude-integrated encephalography (aEEG) is increasingly being used in 
neonatal intensive care units (NICU) for continuous monitoring of cerebral electrical 
activity in critically ill newborns [28, 33]. The presence of hypoxic-ischemic injury 
can be determined by specific EEG patterns, including burst suppression, very low 
voltages, and an isoelectric/flat trace [34-39]. The limitation of aEEG for early 
diagnosis of abnormal brain energy function stems from its poor sensitivity [40]. 
Normal EEG activity has been documented in newborns with clinical evidence of 
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brain death [41] and, conversely, newborns can present a flat trace EEG signal in the 
first hours after HI and yet continue to develop normally [41]. 
The lack of current clinical techniques to diagnose HI within the therapeutic 
window has created a need for newer techniques capable of accurately detecting the 
onset and severity of brain insult within the critical first hours following birth. The 
strong correlation between mitochondrial dysfunction and insult severity suggests that 
a non-invasive measure of the cerebral metabolic rate of oxygen (CMRO2) could 
improve early prognosis of HIE. The interest in NIRS stems from its portability, 
which enables bedside monitoring, and its sensitivity to blood oxygenation, which 
can be related to the energy demands of tissue. Section 1.8 will discuss how CMRO2 
can be measured by near-infrared spectroscopy (NIRS). This section will be followed 
by review of previous studies using NIRS to assess the effects of HI on cerebral 
energy metabolism. The last section is a discussion on clinical studies using NIRS to 
measure CMRO2 in newborns. 
 
1.5 Near-Infrared Spectroscopy (NIRS) 
 The relative transparency of tissue to near-infrared light (700-1000 nm), 
coupled with the unique absorption properties of oxy and deoxy hemoglobin (HbO2 
and HHb, respectively) enable tissue blood oxygenation to be assessed by NIRS [42]. 
The concentration of endogenous light absorbers, which are referred to as 
chromophores, can be determined by the loss of light intensity as light passes through 
tissue. Ignoring for the moment the scattering of light in tissue, the change in light 
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intensity can be related to the concentration of a chromophore by the Beer-Lambert 
Law:  
                                   (1.1) 
where A is the absorption of light as it passes through the medium, C is the 
chromophore concentration in the medium, ε is the specific extinction coefficient of 
the chromophore, and L is the physical distance that the light travelled. Absorption is 
defined as the log of the ratio of light intensity emitted (I0) to the intensity detected 
(I). Equation 1.1 can be expanded to account for multiple chromophores, each with its 
own specific extinction coefficient:  
                                        (1.2) 
 
where λ is wavelength , εi is the specific absorption of the ith chromophore, and Ci is 
the concentration of the ith chromophore. The concentration of each can be 
determined by acquiring absorption measurements at multiple wavelengths. 
 
1.5.1 Main Endogenous Chromophores  
Although water is a weak absorber of NIR light, its contribution to the overall 
absorption is significant because of its large abundance in tissue: 80% in the adult 
brain and 85% in the newborn brain [43]. The high absorption of water at 
wavelengths greater than roughly 1000 nm sets the upper limit of the NIR spectrum 
for probing biological tissue [44]. There are three distinct absorption peaks for water 
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within the NIR range at 740, 840 and 925 nm. Although water absorption has not 
received nearly the attention of hemoglobin in NIRS studies, its stable concentration 
in tissue, particularly brain, and its unique absorption features provides a unique 
method of quantifying NIRS measurements, as will be discussed in section 1.7.  
Of all of the endogenous NIR chromophores, hemoglobin has the largest 
attenuation peak due to its high absorption and concentration [44, 45]. The two most 
common forms of hemoglobin are hemoglobin alpha (HbA) and fetal hemoglobin 
(HbF). The latter is found in newborns; however, its specific absorption spectrum is 
the same as HbA. The physiological and clinical interests in NIRS primarily stems 
from the unique absorption spectra of HHb and HbO2 (Figure 1.2). By acquiring 
measurements at multiple wavelengths, the difference in absorption spectra between 
HHb and HbO2, provides a means of determining each concentration, from which 
tissue oxygenation extraction (fraction) (OEF) can be determined:  
 
	
  – 	   1.39  
Arterial O	
 
(1.3) 
Analogous to the upper limit placed by water, the strong absorption of 
hemoglobin at wavelengths below 600 nm sets the lower limit of the biological 
window. 
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Figure 1.2–Absorption spectra of endogenous chromophores 
 
The absorption spectra of water (H2O), deoxy-hemoglobin (HHb), and oxy-
hemoglobin (HbO2) within the near-infrared range.  
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1.6 In-vivo Spectroscopy  
 In 1977 the first in vivo study demonstrating the sensitivity of NIRS to brain 
oxygenation was performed in an animal model by Jobsis et al. [42]. Subsequent 
studies extended this method to human adults [46] and newborn infants [47]. 
However, the main challenge to in vivo spectroscopy is light scattering. Scattering in 
tissue disperses and diverges the transmitted light, reducing the intensity that can be 
detected. Scattering has wavelength dependence and alters the linear relationship 
between light absorption and the concentration of the chromophores. One method for 
characterizing the effects of light scattering in tissue is to modify the Beer-Lambert 
Law to account for the non-linear path that scattered light takes through tissue:  
    (1.4) 
where β is called the differential pathlength which is much greater than the physical 
distance between the light source and detector due to light scattering. The additional 
factor G accounts for the attenuation of light in tissue due to scattering [48]. This 
equation demonstrated that measuring chromophores’ concentrations requires 
removing the effects of losses in absorption due to scattering and determining the 
differential pathlength.   
 The work presented in this thesis uses a NIRS technique referred to as second 
derivative spectroscopy to quantify the concentrations of chromophores, as described 
by Matcher et al.  [44]. Second derivative NIRS relies on the principle that both β and 
G have a weak dependence on wavelength. Therefore, if the second derivative of 
( ) ( ) ( ) ( )λλελβλ GCA ii +=
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equation 1.4 is taken with respect to wavelength, G and any derivative terms with 
respect to β will disappear, leaving: 
    (1.5) 
Assuming a constant water concentration, the mean pathlength can be 
determined using the water features at 740 and 840 nm. Since the HHb absorption 
spectrum has a strong characteristic at 770 nm, the water-derived differential 
pathlength can be used to calculate the absolute concentration of HHb. This approach 
is reasonable in the brain because the water concentration is extremely stable and 
only changes a few percent, even after HI [49]. The second main assumption of this 
technique is that the tissue volume interrogated is homogeneous, which is reasonable 
for newborns since the skull and scalp are relatively thin compared to adults.  
 
1.7 Measuring Cerebral Blood Flow by NIRS  
 Cerebral blood flow (CBF) can be measured by NIRS by tracking the uptake of 
a blood flow tracer into brain tissue. The initial approach used a small transient 
change in arterial oxygenation as an endogenous (HbO2) tracer [44, 50-53], and it has 
been validated by comparison with CBF measurements obtained with the 133Xenon 
tracer clearance technique [54]. However, this method is limited by its poor precision 
and sensitivity [50]. An alternative approach is to use the light absorbing dye, 
indocyanine green (ICG), as an exogenous contrast agent. Indocyanine green is a 
water-soluble tricarbocyanine dye that is strongly protein bound (95%) in blood and 
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has a relatively short biological half-life (~5 min). The dye has a unique absorption 
spectrum with a peak absorbance around 800 nm. When injected into the blood 
stream, it rapidly binds with plasma proteins (albumin or lipoproteins), causing a shift 
in its absorption spectrum with a new peak at 805 nm [55]. The first use of ICG for an 
NIRS application was by Colacino et al. to study cerebral hemodynamics in ducks 
[54]. Indocyanine green has a high safety record in human applications [56-61]. 
Hope-Ross et al. conducted a safety study of 3149 adult patients suffering from 
ophthalmia [62].  They reported that the frequencies of mild, moderate and severe 
side effects were 0.15%, 0.2% and 0.05%, respectively. The first application 
involving human newborns was by Patel et al. [63], who compared the SO2 
manipulation and ICG methods of measuring CBF in newborns, and demonstrated a 
strong correlation between the CBF values determined by the two techniques (r = 
0.93). However, the requirement of rapid changes in arterial oxygen saturation is 
difficult to achieve in newborns. For the HbO2 method, 45% of the measurements 
collected did not meet the quality criteria and had to be neglected, as opposed to only 
11% for the ICG technique. This is related to the greater precision observed with the 
ICG method: 85%, compared to 76% for HbO2. 
 Cerebral blood flow and other hemodynamic parameters, cerebral blood volume 
(CBV) and mean transit time (MTT) can be determined by monitoring the dynamic 
change in the brain concentration of ICG following an intravenous bolus injection 
[64]. With this approach, which is analogous to dynamic contrast-enhanced 
techniques used with computed tomography and magnetic resonance imaging [65], 
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the time-varying concentration of ICG in brain is modeled as a linear time-invariant 
system: 
                                !    " #$%! & $'$()                          (1.6) 
This equation is more commonly written in its condensed form: 
                                   !   · #!  %!                                              (1.6b) 
Where  is the convolution operator, Q(t) and Ca(t) are the amount of ICG in the 
brain and arterial blood, respectively (Figure 1.3), F represents cerebral blood flow 
and R(t) is referred to as the impulse residue function (Figure 1.4). It represents the 
amount of ICG in the brain region at any time t following an idealized bolus injection 
of unit concentration. Equation (1.6) indicates that in order to measure F, the time-
dependent arterial and brain concentration must both be measured. With this 
technique, Q(t) is determined by 2nd derivative NIRS and Ca(t) is measured non-
invasively by dye densitometry [66]. A deconvolution algorithm can be applied to the 
time-concentration data to extract a flow-scaled R(t). Cerebral blood flow is given by 
the initial height of the function, since by definition R(t) is initially equal to one, and 
the area under the function is equal to CBV. The MTT can be determined by the 
central volume principle, i.e., CBV = MTTCBF [67]. Because deconvolution is 
extremely sensitive to noise, all data were analyzed using a stable algorithm that was 
developed specifically for ICG experiments [66].  
  
∗
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Figure 1.3– Sample Arterial and Tissue ICG concentration curves 
 
Representative tissue and arterial ICG concentration curves measured with NIRS and 
the dye densitogram unit. The peak arterial concentration is approximately 20 times 
greater than that of tissue concentration since the cerebral blood volume is about 5% 
of the total brain volume.  
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Figure 1.4– Sample flow-scaled impulse residue function 
 
CBF-scaled impulse residue function [FR(t)]. The height of initial plateau equals 
CBF and the area under the curve is CBV.
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1.8 Cerebral Metabolic Rate of Oxygen 
 The cerebral metabolic rate of oxygen can be determined using the Fick 
Principle [68]: 
                                      #+%  #, · 	 & 	
        (1.7) 
where [O2]a is the arterial oxygen concentration and [O2]v is venous oxygen 
concentration, which can be determined using the NIRS measurements of tissue 
[HHb]. Since NIRS measures the total blood [HHb], this procedure requires assuming 
a relative distribution of blood in arterial, capillary and venous blood compartments: 
20%, 10%, and 70% respectively [69]. The venous concentration of oxygen is 
determined by:  
         -./0$1 	  2	3 & 443  
	6
#,-78 & 
1
3  	9:; 7 1.39
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>  
   
(1.8)
             
 
 This method has been validated in vivo in newborn piglets by comparison to 
CMRO2 derived from directly measuring the oxygenation of venous blood collected 
from the superior sagittal sinus. In one study [70], piglets were subject to five cerebral 
metabolic states created by different anesthetics. No significant differences were 
found between CMRO2 measurements obtained from NIRS venous oxygen 
measurements and those obtained from sagittal-sinus blood samples at any anesthetic 
level. Across all metabolic conditions, a strong correlation between the two 
techniques was found (R2 = 0.88). The same validation approach was used in a 
subsequent study to demonstrate the accuracy of the NIRS CMRO2 measurements 
following HI [71]. 
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1.9 Assessing the Effects of Hypoxia-Ischemia on Cerebral Energy 
Metabolism by NIRS 
 There have been several studies that have used NIRS to assess the effects of HI 
on cerebral oxygenation and blood flow. Recently, Kurth et al. 2009 [72] investigated 
the relationship between HI duration and cerebral oxygen saturation (ScO2) to 
establish a viability threshold that predicts neurological outcome. A correlation 
between the duration of ScO2 below 35% and neurological outcome was reported, 
suggesting that this NIRS measure of injury duration could be used to predict 
neurological outcome. In contrast, Ioroi et al 2002 [73] demonstrated in newborn 
piglets that ScO2 quickly recovered to baseline values during reperfusion, despite 
evidence of reduced brain activity measured by aEEG. The inability to detect post-HI 
alternations in brain activity suggests that a more sensitive NIRS marker of cerebral 
energy metabolism is required. One approach is to use NIRS to measure CMRO2 
using the technique outlined in section 1.8.  
 Tichauer et al. was the first to use NIRS to investigate potential post-insult 
changes in CMRO2 [71, 74, 75]. In an animal model of neonatal HI, CMRO2 was 
found to be suppressed after HI and remained significantly depressed compared to 
pre-HI values for 6 h. Interestingly, post-HI CBF and [HHb] values between controls 
and HI groups were not significantly different after 30 min of reperfusion, 
demonstrating the importance of measuring CMRO2 directly. In a subsequent paper, 
post-HI suppression in cerebral metabolism was strongly correlated with the duration 
of HI at 12 h after the insult [74]. It was postulated that the delay in the correlation 
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between insult duration and cerebral metabolism could be attributed to the effects of 
anesthesia. In a subsequent study, experiments were repeated using a lighter 
anesthetic (fentanyl) and it was shown that the correlation between CMRO2 and HI 
was observable 45 min after the insult [75]. It was also demonstrated that a linear 
relationship between the mean voltage measured by amplitude-integrated EEG and 
CMRO2 existed. This latter result brings up an important question regarding the 
mechanisms controlling cerebral energy metabolism following HI: Do the changes in 
CMRO2 reflect mitochondrial dysfunction, as discussed above in Section 1.3.2, or do 
they reflect a reduction in energy demand due to reduced electrocortical activity, as 
suggested by the correlation with EEG [75]?   
 Understanding the possible mechanisms controlling cerebral energy metabolism 
during the reperfusion phase would help assess the value of CMRO2 as a clinical 
marker of HI. That is, if metabolic depression observed by NIRS indicates 
mitochondrial impairment then it could be used as an early marker of secondary brain 
injury. As discussed in Section 1.3.2, the potent effects of NO on mitochondrial 
energy production could be involved in the observed CMRO2 suppression post HI 
[76]. Not only does elevated NO help to ‘kick start’ the processes leading to delayed 
brain injury, it has the immediate effect of inhibiting mitochondrial respiration [20]. 
Administration of NO inhibitors after HI has been shown to reduce brain injury and 
improve energy metabolism [77, 78]. To test whether impaired mitochondrial energy 
production is related to suppressed energy metabolism post HI, Winter et al. 
examined the relationship between CMRO2 and the high-energy metabolites, 
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measured by magnetic resonance spectroscopy. A general recovery of the metabolites 
despite reduced CMRO2 was observed during the early recovery period, suggesting 
sufficient energy production [79]. 
 Another possible mechanism responsible for decreased CMRO2 following HI is 
the increase in extra-cellular adenosine concentration. Adenosine A1 receptors in the 
brain are known to greatly influence cerebral synaptic activity by mediating cell 
membrane polarization and controlling neuronal firing. During HI, the breakdown of 
ATP results in increased concentrations of adenosine and ADP. The accumulation of 
extra-cellular adenosine in the brain is known to lead to hyper-polarization of cells, 
greatly reducing synaptic activity and therefore depressing the brain’s energy 
demands [80]. This may explain the similar reductions in magnitude of post-HI 
CMRO2. Recently, an adenosine receptor antagonist was shown to abolish the 
metabolic depression during hypoxia in fetal sheep [80]. However, the role of 
adenosine following neonatal HI is unclear since adenosine antagonists were shown 
to have little effect on the extent of brain injury in neonatal rats [81]. The lack of an 
effect in these experiments may have been due to the severity of the hypoxic-
ischemic insult. Clearly, there is a need to better understand the mechanisms 
controlling post-HI oxidative metabolism and how they relate to delayed brain injury 
considering that changes in CMRO2 are one of the earliest measurable events 
following HI. Understanding these adenosine-mediated mechanisms is the focus of 
the experiments presented in chapter 3. 
1.10 Clinical Applications of NIRS in CBF and CMRO2 
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Measurements 
 An understanding of the rate of oxygen delivery and blood flow in sick infants 
undergoing intensive care is an important aim of neonatal diagnostic care. As NIRS is 
portable, safe and non-invasive, it is ideal for clinical studies. As early as 1988, one 
of the first NIRS studies measured CBF in newborns undergoing indomethacin 
treatment for asphyxiation [82]. A sizable reduction in CBF from 18 ml/min/100g to 
7 ml/min/100g after treatment was observed due to the vaso-constrictive property of 
indomethacin. Bucher et al. validated NIRS CBF measurements by a comparison to 
measurements obtained with the 133xenon clearance technique [51]. A similar 
comparison was conducted by Skov et al.[83] on newborns, showing that there was a 
strong correlation between the two techniques (R2 = 0.84, p < 0.0001). Since these 
validation studies, there have been several studies using NIRS to assess CBF in 
newborns with neurologic injuries. Meek et al. [84] showed that CBF is significantly 
declined in preterm newborns suffering from intraventricular hemorrhages, while 
Bellinger et al. [85] observed that newborns showed increased brain perfusion while 
undergoing hypothermia treatment during cardiopulmonary bypass surgery. A good 
compilation of similar NIRS perfusion studies is given by Chakravarti et al. [86]. 
 Yoxall et al. [87] was the first group to measure cerebral oxygen consumption 
(CMRO2) in newborns using NIRS. They were able to show that oxygen metabolism 
is linearly related with increasing gestational age and their values were in a good 
agreement with values obtained in other more invasive studies. In a subsequent study, 
Kissack et al. showed that increased oxygen consumption during the first 3 days after 
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birth indicated increased cerebral activity as result of normal adaptation to 
extrauterine life [88]. Elwell et al. [89], reported a good agreement between their 
NIRS CMRO2 measurements and previous values obtained with PET [90]. Recently, 
Roche et al.[91] followed 56 premature newborns of various gestational age and 
showed that relative CBF and CMRO2 correlate better with postnatal age (R= 0.37 
and 0.43, respectively) compared to SO2 (R= -0.07). They concluded that, in the 
premature newborns, relative CBF and CMRO2 measurements are more accurate 
biomarkers of the brain development than SO2. In a follow-up study they 
demonstrated that NIRS could be used to measure regional developmental changes in 
CBF and CMRO2 in newborns [92], similar to earlier studies using PET [93] and 
single-photon emission computed tomography (SPECT) [94].
 
 The majority of these clinical NIRS studies use the HbO2 flow tracer method to 
measure CBF, rather than an endogenous dye such as ICG. As mentioned earlier, this 
method suffers from poor repeatability and low precision compared to the ICG bolus-
tracking approach. The appendix of this thesis will discuss a study using the 
NIRS/ICG technique to measure CBF in preterm newborns undergoing drug therapy 
for a common heart condition, patent ductus arteriosus.  
 
 
1.11 Research Objective 
I.   To provide a clearer understanding of the relationship between early changes 
in CMRO2 and brain injury, the goal of the present study was to investigate a 
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potential mechanism underlying the observed reductions in CMRO2 following 
HI. Elevated adenosine levels, as observed during HI, are known to inhibit 
synaptic activity and reduce metabolic demand via adenosine A1 receptor. 
Studies have shown that blocking these adenosine receptors during hypoxia 
(ischemia) with a specific adenosine A1 receptor antagonist, 8-cyclopentyl-
1,3-dipropylxanthine (DPCPX), diminished the cerebral metabolic depression 
during hypoxia. The objective of this study was to investigate if the same 
adenosine A1 receptor antagonist affects the CMRO2 and synaptic activity 
(aEEG) depression following HI in neonatal piglets.  
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CHAPTER 2 - METHODS & MATERIALS 
 2.1 Animal Preparation 
The study was approved by the Animal Use Subcommittee of the Canadian 
Council on Animal Care at the University of Western Ontario. Newborn Duroc 
piglets were delivered from a local supplier on the morning of the experiment. All 
surgical procedures were performed under 3% isoflurane. Piglets were 
tracheotomized and mechanically ventilated on a 2:1 oxygen/medical-air mixture. 
Two incisions were made lateral to the trachea, and vascular occluders (In Vivo 
Metric, Healdsberg, CA) were placed around both carotid arteries just proximal to the 
carotid bifurcation. A cannula was inserted into an ear vein for injecting the NIRS 
contrast agent (indocyanine green, ICG) and another cannula was inserted into a belly 
vein for infusing 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and fentanyl. A final 
cannula was inserted into a femoral artery for continuous monitoring of blood 
pressure and to allow the collection of arterial blood samples for gas and glucose 
analysis. Following surgery, isoflurane was reduced to 1.75%, and piglets were 
allowed to stabilize for 1h before the experiment started. 
2.2 Experimental Procedure 
Piglets were randomly divided into two groups: a drug group (i.e. those who 
received DPCPX) and a control group (i.e., those who received the vehicle). For the 
baseline NIRS measurements of CBF and CMRO2, the anesthetic was switched from 
isoflurane to a combination of an i.v. infusion of 0.02 mg/kg/h fentanyl and the 
inhalation of 30% oxygen/70% N2O gas mixture. Two measurements were acquired, 
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separated by 10 min to allow time for the concentration of ICG in the blood to 
equilibrate. The anesthetic was switched to fentanyl/nitrous oxide because this 
combination has less of an effect on cerebral metabolism than isoflurane [95]. 
Following the baseline measurements, isoflurane anesthesia was reinstated for the 
hypoxic-ischemic insult to replicate the HI protocol used in our previous studies [71, 
74, 75]. After a period of 45 min, a hypoxic-ischemic insult was induced by clamping 
both carotid arteries and reducing the fraction of inspired oxygen to 7%. Based on a 
threshold established in our previous study, ischemia was defined when the mean 
arterial pressure (MAP) fell to less than 70% of baseline [74]. All piglets were then 
subjected to 10 min of ischemia, after which the carotid clamps were released and the 
fraction of inspired oxygen returned to baseline levels.  
For the drug group, DPCPX was infused intravenously for 30 min prior to the 
start of HI, discontinued during HI, and then continued again for another 30 min after 
the insult had ended. DPCPX infusion was paused during HI as a precaution because 
this drug is known to elevate heart rate, which can lead to cardiac arrest during 
stressful conditions [96]. DPCPX was prepared in 0.1M NaOH to a concentration of 
2.5mg/min with a final pH of approximately 10. The drug was infused at a rate of 2.5 
mg/min for the first 10 min and at 0.75 mg/min for the reminder of the infusion 
period [80]. The same infusion protocol was followed for the control group using 
only the vehicle (no DPCPX). After the hypoxic-ischemic insult, the anesthetic was 
again switched from isoflurane to the fentanyl/N2O mixture. After 30 min of 
reperfusion, four NIRS measurements of CBF and CMRO2 were collected with each 
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measurement separated by at least 10 min to allow time for ICG clearance. EEG data 
were collected continuously throughout the study.  
At all times during the experiment (excluding the insult), arterial PCO2 was 
maintained between 38–42 Torr by adjusting the respiratory rate, and arterial PO2 was 
maintained between 100–150 Torr by adjusting the ratio of oxygen to medical air. 
Blood glucose was kept between 3 and 8 mmol/l by intermittent 0.3-ml injections of a 
25% dextrose solution into an ear vein. A water-heating blanket was used to maintain 
a rectal temperature between 37 and 38°C. Arterial pH and heart rate were also 
monitored. 
2.3 Near-Infrared Spectroscopy 
NIRS data were collected with a continuous-wave, broadband (600 –1,000 
nm) system with a single emission fiber-optic bundle and a single detection bundle 
[66]. The end of each bundle was placed 3 cm apart, parasagittally on the head, 
proximal to the widest part of the brain. The bolus-tracking technique for measuring 
CBF involved measuring the time-dependent concentration of ICG in arterial blood 
and brain tissue following a rapid intravenous injection of the dye (0.1 mg/kg). The 
arterial blood ICG concentration curve was measured by a dye densitometer attached 
to a front paw and the brain ICG concentration curve by NIRS. Both concentration 
curves were acquired over a period of approximately 60 s, and a deconvolution was 
applied to the data to extract estimates of CBF, cerebral blood volume (CBV) [66] 
and subsequently CMRO2. The exact methods used to calculate CBF and CMRO2 by 
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NIRS have been outlined in detail previously [66, 68, 70] and briefly in the 
introduction (Chapter 1 Sections 1.7 and 1.8). 
2.4 Electroencephalography 
To assess electrocortical brain activity, needle electrodes were inserted to 
record from the left and right parietal regions of the brain. The signal was recorded at 
a sampling rate of 250 Hz after being amplified and filtered (0.1–100 Hz) using a 
high-performance AC preamplifier (model P511, Grass Technologies Product Group, 
Astro-Med, West Warwick, RI). An algorithm developed in MATLAB (The 
MathWorks, Natick, MA) was used to convert the raw EEG data to an aEEG signal 
[75]. Data were filtered, rectified, and integrated over a window of 100 ms. To 
eliminate non-physiological signal components and to attenuate the dominant delta-
wave patterns, a series of filters were applied to mimic those used in the Cerebral 
Function Monitor [97]. The final signal was plotted logarithmically, and the resulting 
aEEG was analyzed by two different methods: a quantitative mean aEEG background 
technique and a qualitative neural activity score technique. 
The mean aEEG background signal was measured by drawing a line through 
the upper and lower margins of the aEEG band, as described by al Naqeeb et al. [37]. 
In this way, individual spikes separated from the aEEG band are excluded from the 
measurement. The median line between the upper and lower margins was taken to be 
the mean amplitude. A neural activity score, reflecting the functional state of the 
brain, was calculated based on the background voltage and pattern recognition. 
Specifically, the background voltage was graded as normal, low, or extremely low. 
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The background pattern was classified as either continuous or discontinuous, and the 
presence of seizure activity or burst-suppression pattern was noted [98]. The aEEG 
data from each experiment were scored in 10-min intervals and then grouped to 
calculate a mean neural activity scores for baseline and reperfusion periods. 
2.5 Statistical Analysis 
SPSS 17.0 (SPSS, Chicago, IL) was used for all statistical analyses. A two-
way, mixed analysis of variance (ANOVA) with Bonferroni post-hoc correction was 
used to compare measurements between drug and vehicle/control groups, with time as 
the within-subjects variable and treatment as the between-subjects variable. The 
analysis was conducted for average pre- and post-HI values of CBF, OEF, CMRO2 
and EEG. When appropriate, group differences at individual time periods were 
investigated by a Student’s t-test. For nonparametric data, such as the neural activity 
scores, the Spearman’s rank test was used. Statistical significance for all tests was 
based on a P < 0.05. All values are presented as means ± SE.  
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CHAPTER 3 - RESULTS 
A total of 20 piglets (9 males, 11 females) were studied. Three females in the 
drug group could not be revived during HI due to cardiac complications and were 
therefore excluded from the results. There were a total of 10 piglets in the drug group 
and 7 in the control group (average age: 27 ± 5 h, weight: 1.58 ± 0.06 kg). Table 3.1 
summarizes the results of the physiological parameters for each group at baseline and 
during reperfusion. No significant differences were found between the two groups for 
any of these parameters. Although both groups showed a trend of increased heart rate 
after HI, this effect did not reach significance. All other physiological parameters 
remained within their normal range.  
The duration of ischemia, as defined by MAP below 70% of baseline, was not 
significantly different between the two groups: 10 ± 1.58 min for the vehicle group 
and 10.92 ± 1.48 min for the drug group. However, the total duration of carotid 
clamping and reduced inspired oxygen was significantly longer for the drug group 
(25.3 ± 1.45 min) compared to the vehicle group (14.4 ± 1.86 min). This difference 
suggests that DPCPX delayed the onset of loss of autoregulation caused by HI.  
Figure 3.1 presents average CBF, OEF and CMRO2 values for the drug and 
vehicle groups at baseline and during reperfusion. Significant time (p < 0.001) and 
treatment effects (p < 0.001) were found for CBF, but no overall time-by-treatment 
interaction was observed. Average baseline CBF values for the vehicle and drug 
groups were 50.86 ± 3.59 and 60.58 ± 5.67 ml/min/100g, respectively, which were 
not significantly different. In both groups, CBF fell by roughly 20% following HI to 
31 
 
 
 
40.55 and 48.5 ml/min/100g for the vehicle and drug group, respectively. Figure 3.1B 
presents the average OEF values for the two groups pre- and post-HI. No significant 
time or treatment effect was found, nor was there a significant time-by-treatment 
interaction. 
Figure 3.1C presents the average CMRO2 values for the drug and vehicle 
groups at baseline and after reperfusion. A significant time-by-treatment interaction 
was found (F(3,66) = 4.81, p < 0.05, power = 0.68) with a significant overall time 
effect (p < 0.001). The source of the interaction was the difference in the post-HI 
CMRO2 values (p < 0.05), whereas, there was no significant difference between 
groups at baseline. Average baseline values were 2.71 ± 0.06 and 2.52 ± 0.12 ml 
O2/min/100g for the vehicle and drug groups, respectively. A significant decrease in 
CMRO2 was observed for the vehicle group compare to baseline, with an average 
post-HI value of 1.88 ± 0.18 ml O2/min/100g (p < 0.001). For the drug group, 
CMRO2 decreased to 2.25 ± 0.21 ml O2/min/100g after HI, but this change was not 
significant from its baseline value. 
Figure 3.2A presents the average aEEG values for both groups at baseline and 
during reperfusion. There were overall significant time (p < 0.01) and treatment (p < 
0.01) effects, as well as a significant time-by-treatment interaction (F(3,66) = 3.9, p < 
0.05, power = 0.70). There was no significant difference in baseline aEEG 
measurements between the two groups with average values of 48.5 ± 1.6 and 50 ± 
1.52 µV for the vehicle and drug group, respectively. Post-hoc analysis revealed a 
significant difference between the two groups following HI (p < 0.01). For both 
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groups, aEEG dropped significantly after HI:  34 ± 5.6 µV for the drug group (p < 
0.01) and 21.8 ± 4.8 (p < 0.001) for the vehicle group. A significant difference in the 
time between the start of HI and the resulting reduction in aEEG activity was also 
observed (Figure 3.3). This delay was significantly shorter for the vehicle group (3.67 
± 1.03 min) compared to the drug group (15.2 ± 3.97 min).  
Figure 3.2B presents the averaged neural score values for the two groups 
before and after HI. Significant time (p < 0.001) and treatment (p < 0.001) effects and 
a significant time-by-treatment interaction were observed (F(3,66) = 39.7, p < 0.001, 
power = 0.86). For piglets in the drug group, the average neural score dropped to 3.3 
± 0.4 during the reperfusion period. However, this difference was not significant 
compared to baseline. The neural score for the vehicle group dropped significantly to 
2.1 ± 0.4 (p < 0.001) during the reperfusion period. An inter-group comparison 
showed there was a significant difference in neural scores between the post HI 
periods of the 2 groups (p < 0.001). 
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Table 3.1 Physiological variables for the drug and vehicle groups before insult 
(baseline) and during reperfusion. 
 
 
 Baseline Post Insult 
Mean Arterial Pressure (Torr) 
Vehicle  70.4 ± 1.53 67.67 ± 2.29 
Drug 65.54 ± 2.46 67.07 ± 2.03 
 
Heart Rate (beats/min) 
Vehicle  197.25 ± 7.47 206 ± 5.82 
Drug 171.84 ± 10.16 201.24 ± 12.7 
   
Arterial pCO2 (Torr) 
Vehicle  40.18 ± 1.08 39.69 ± 0.66 
Drug 39.72 ± 0.87 39.53 ± 0.69 
   
Arterial pO2 (Torr) 
Vehicle  123.13 ± 5.23 128.25 ± 2.68 
Drug 123.36 ± 2.84 122.7 ± 2.63 
   
Arterial pH 
Vehicle  7.37 ± 0.05 7.35 ± 0.03 
Drug 7.40 ± 0.04 7.41 ± 0.03 
                          Values are mean ±SE  
 
  
 Figure 3.1 Comparison of (A) cerebral blood flow (CBF), (B) oxygen extraction 
fraction (OEF) and (C) cerebral metabolic rate of oxygen (CMRO
treatment (DPCPX) and vehicle groups at baseline and after HI. Error bars represent 
SE and * indicates statistical s
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Figure 3.2 Comparison of (A) 
(aEEG) and (B) neural scores between treatment (DPCPX) and vehicle groups at 
baseline and post HI. Error bars represent SE 
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Figure 3.3 Continuous amplitude-integrated electroencephalography (aEEG) 
recording plotted against time for one animal in the treatment (DPCPX) group (A) 
and another animal in the vehicle (B). *indicates start of drug/vehicle infusion, ** 
indicates start of insult conditions and *** indicates the end of insult.  
A 
B 
Delay Period 
* 
*** 
* 
Delay Period ** 
** 
*** 
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CHAPTER 4 - DISCUSSION 
  The brevity of the therapeutic window highlights the need to quickly identify 
infants at risk of HIE in order to maximize treatment efficacy [99]. One approach is to 
measure cerebral energy metabolism since impaired metabolism has been suggested 
as an early marker of delayed brain injury [16]. Our group and others have previously 
shown in an animal model of HI that CMRO2 is depressed following an hypoxic-
ischemic insult; however, the mechanisms controlling post-HI CMRO2 were unclear 
[71, 74, 77, 78]. The principle finding of the current study was that the administration 
of the adenosine A1 receptor antagonist, DPCPX, significantly reduced the metabolic 
depression following moderate HI. Considering that adenosine concentrations are 
known to rise during HI and have been shown to substantially suppress electrocortical 
synaptic activity [100-102], these results suggest that the observed post-HI reduction 
in CMRO2 was most likely due to reduced cerebral energy demands. This conclusion 
was substantiated by the results from the concurrent aEEG recordings, which 
displayed significantly less electrocortical suppression after HI in animals 
administered DPCPX.  
The role of adenosine in suppressing electrocortical activity and cerebral 
energy metabolism under conditions that lead to oxygen deprivation has been 
demonstrated in a number of studies. Administrating DPCPX in near-term fetal sheep 
undergoing 10 min of umbilical cord occlusion was shown to delay the rapid decline 
in EEG intensity that was observed at the beginning of cord occlusion in control 
animals [103]. Similarly, the time to electrocortical suppression following global 
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cerebral ischemia was significantly longer in rats administered DPCPX [104]. This 
specific adenosine A1 receptor antagonist has also been shown to increase the 
recovery rate of spontaneous electrocortical activity following transient global 
ischemia [105]. Regarding cerebral energy metabolism, Blood et al. showed that 
DPCPX completely abolished the reduction in cortical heat production – an indicator 
of cortical metabolism [103] – that occurs during cerebral hypoxia [80]. DPCPX 
treatment was also found to attenuate the reduction in heat production during cord 
occlusion [106]. The results of the current study are in good agreement with these 
previous studies. In piglets treated with DPCPX, the suppression of EEG activity 
following the onset of HI was delayed by approximately 10 min compared to 
controls. Furthermore, post-HI CMRO2 and mean aEEG voltage were significantly 
greater in treated animals, although the latter remained below pre-HI values in both 
groups. This general agreement suggests that activation of the adenosine A1 receptor 
due to the rise in adenosine concentrations during HI is the primary reason for 
reduced CMRO2 following an hypoxic-ischemic insult. It is generally considered that 
the adenosine-induced reduction in cerebral metabolism is a neuroprotective response 
[107, 108]. For instance, Halle et al. demonstrated that enhancing the binding of 
adenosine to its A1 receptors resulted in substantially reduced brain injury following 
HI in newborn rats [109].  
In contrast to the above findings, Jensen et al. reported that treatment with 
DPCPX had little to no effect on cerebral metabolism or EEG intensity in fetal sheep 
exposed to 10 min of asphyxia [110]. Compared to baseline values, significant 
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reductions in EEG intensity and cortical heat production were observed during the 
first 4 h after occlusion. One possible reason for the discrepancy between the two 
studies could be differences in the severity of asphyxia. The 10-min cord occlusion 
model was classified as a severe injury as demonstrated by significant neuronal loss 
[111]. In the current study, all piglets were subjected to 10 min of ischemia; however, 
the severity of ischemia is likely less than during complete cord occlusion due to 
residual blood flow through the vertebral arteries [71]. Furthermore, the correlation 
between the degree of neuronal damage, as indicated by the number of Fluoro-Jade B 
positive cells, and ischemia duration would indicate that a 10-min insult would likely 
be classified as a mild-to-moderate injury [74]. This explanation would also agree 
with the reported differences in the effects of DPCPX on cerebral metabolism during 
hypoxia [80], which showed attenuation of metabolism post-HI, compared to severe 
asphyxia [106] which did not. Another explanation could be the difference in the 
DPCPX infusion protocol used in the two studies. With the cord occlusion model, the 
DPCPX infusion was stopped at the end of the occlusion period, whereas, in the 
current study the infusion was continued for another 30 min. It may be that the 
infusion during the early post-HI period was necessary to abolish the effects of 
residual adenosine from the hypoxic-ischemic period. 
  The results of the current study also complement the findings of our previous 
study that combined NIRS measurements of CMRO2 with phosphorous (31P) and 
proton (1H) magnetic resonance spectroscopy [79]. In that study, a general recovery 
of high-energy metabolites and a reduction in lactate concentration in the brain were 
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found during the recovery period following 30 min of HI, despite depressed CMRO2. 
It was postulated that the discrepancy between CMRO2 and metabolite levels 
reflected a reduction in cerebral energy demands following HI rather than impaired 
energy production. Similar results were found in the current study as evident by the 
concurrent reductions in post-HI aEEG intensity and CMRO2 in the control animals. 
Furthermore, the increase in both of these measures in the DPCPX-treated animals 
suggests a possible mechanism to explain these findings. 
  Another potential mechanism contributing to the metabolic changes observed 
following HI is nitric oxide. Increased neuronal and inducible nitric oxide synthase 
(NOS) expression has been observed during the first 6 h following HI [18, 112], and 
it is known that elevated NO levels can reduce mitochondrial respiration by inhibiting 
cytochrome c oxidation. [20, 113]. Peeters-Scholte et al. demonstrated in newborn 
piglets that the use of selective (neuronal and inducible) NOS inhibitors, following 60 
min of HI, reduced brain cell damage and improved the cerebral energy state, as 
characterized by the recovery of the concentration of high-energy metabolites 
(phosphocreatine and ATP) [77]. Dorrepaal et al. demonstrated in fetal lambs that 
infusing a non-selective NOS inhibitor after HI prevented the expected decrease in 
CMRO2 and showed a delayed improvement in electrocortical brain activity [78]. 
One possible link between these studies and the current results is the involvement of 
the adenosine A1 receptor in the up-regulation of nitric oxide synthesis and signaling 
[114, 115]. Using an in-vitro model of cerebral ischemia, Barth et al. demonstrated 
that activation of A1 receptors increased nitric oxide production, which lead to 
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increased neuronal damage [116]. Although these results appear to conflict with the 
concept that adenosine is a neuroprotector, elevated NO production occurred at 
relatively high adenosine concentations (> 10 µM). Further studies involving in-vivo 
models could help to better elucidate the potential relationship between adenosine, 
nitric oxide synthesis, and cerebral metabolism. One approach would be to measure 
markers of elevated NO production in animals treated with DPCPX [76].  
  In the current study, both the DPCPX group and controls showed a significant 
CBF reduction of approximately 20% after HI. Cerebral hypoperfusion has been 
reported previously with other animal models of hypoxia-ischemia [117, 118]. The 
concurrent reduction in both CBF and CMRO2 in the control group suggests that the 
post-HI hypoperfusion is a result of the coupling between CBF and cerebral energy 
metabolism. However, there was no increase in CBF in the DPCPX group despite the 
significant increase in post-HI CMRO2. Instead, a trend of elevated OEF was 
observed, although it did not reach statistical significance. It is difficult to interpret 
the CBF results, as we have observed considerable variability in post-HI perfusion 
changes in previous studies with both significant hypoperfusion and full recovery 
reported [71, 74]. Unlike CMRO2, a significant correlation between CBF and insult 
duration was not observed [75].  
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CHAPTER 5 - SUMMARY 
5.1 Summary 
 The cascade of events leading to the depression of cerebral oxidative 
metabolism after hypoxia-ischemia is complex [7]. The present study demonstrates 
that blocking the adenosine A1 receptor significantly diminished the depression of 
CMRO2 and aEEG typically observed following HI. These results suggest that post-
HI cerebral energy metabolism is at least, in part, controlled by an adenosine-
mediated mechanism. These results complement earlier studies showing similar 
effects in the fetal brain during hypoxia. However, more studies are required to 
determine if this mechanism has a role following more severe hypoxia-ischemia and 
if these changes are ultimately related to the final extent of brain injury. 
5.2 Limitations 
  5.2.1 Limitations of the Near-Infrared Spectroscopy Cerebral 
Metabolic Rate of Oxygen Measurement         
 There are three primary limitations to the NIRS method described for 
measuring CMRO2. The most important is the assumption that the relative arterial and 
venous fractions of the cerebral blood volume are known. NIRS measurements cannot 
distinguish between the arterial, capillary, and venous compartments of the cerebral 
circulation and thus reflect a weighted average of Hb concentrations within these 
different blood compartments in the region sampled. The relative distribution of 
arterial, capillary, and venous compartments in the CBV is generally accepted to be 
approximately 20%, 10%, and 70% respectively [69]. Assuming that the capillary 
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concentration of HHb is the average of arterial and venous concentrations, the final 
CBV distribution would equate to 25% arterial blood and 75% venous blood. There is 
some acceptable variability (10%) in the ratio from individual to individual [119]. 
The second assumption is that the cerebral water concentration is known (85%), 
which is used to calculate the differential pathlength of light. The water content of the 
brain is known to be very stable, and has been shown to only increase by less than 
one percent 24 h after hypoxia-ischemia in neonatal rats [120]. The final potential 
limitation is the use of an exogenous contrast agent to measured CBF. The advantage 
of using indocyanine green (ICG) is increased measurement precision compared to 
CBF measurements obtained with the HbO2 tracer method [63]. However, ICG, like 
all contrast agents, has the risk of causing allergic reactions, albeit fairly small [56, 
57]. Therefore, the clinical use of this technique requires a careful consideration of 
the risks versus the potential benefit. 
  5.2.2 Limitations of Assessing the Effectiveness of DPCPX  
  This study lacked independent measurements of the cerebral adenosine 
concentration to verify an increase after HI. However, elevated adenosine 
concentrations within the brain have been previously demonstrated in rats during 
hypoxia [100], as well as in the blood plasma in patients during ischemia [121]. 
Another potential limitation is that the study did not include any measure of neuronal 
damage, such as by Fluro-Jade staining [74, 122], to determine if the changes in 
CMRO2 caused by DPCPX treatment would exacerbate brain injury. However, this 
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effect has been previously demonstrated [106]. Furthermore, the objective of this 
study was to investigate the mechanisms controlling changes in cerebral energy 
metabolism immediately following HI since an earlier study demonstrated a 
correlation between early CMRO2 changes and the severity of HI [74]. This 
correlation suggests that measuring CMRO2 by NIRS could help to identify newborns 
at risk of developing HIE.  
 5.3 Future Work 
5.3.1 Investigate Alternate Mechanisms Controlling CMRO2 
Post-HI 
  As mentioned in the Discussion, there appears to be two competing 
mechanisms that control CMRO2 after HI: adenosine and nitric oxide. It has been 
suggested that these two mechanisms interact as elevated adenosine levels could 
increase NOS [116], while other studies suggest that they act independently [123]. 
Due to the lack of in vivo evidence, however, how or if adenosine and nitric oxide 
interaction remains to be verified. This is of potential interest for future work using 
the current model of HI in piglets with the adenosine antagonist (DPCPX) and the 
incorporation of a neuronal and inducible nitric oxide (synthase) inhibitor.  
5.3.2 Clinical Implementation of NIRS  
 The NIRS measurements of CMRO2 were shown to be sensitive to a hypoxic-
ischemic injury within the first couple of hours after reperfusion. Furthermore, NIRS 
could be used as a safe, portable, complementary diagnostic tool to accurately predict 
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the extent of brain injury incurred by hypoxia-ischemia and other neonatal brain 
disorders. For example, the technique may have implications in the diagnosis of both 
intraventricular hemorrhage and periventricular leukamalacia, which are common 
forms of brain injury in preterm neonates, and each with hemodynamic and metabolic 
sequelae [33]. Lastly, this technique has the potential to substantially benefit the 
monitoring and care of critically ill and very low birth weight infants requiring 
medical intervention. The appendix of this thesis refers to one recently completed 
pilot study that successfully used this NIRS technique to assess cerebral perfusion and 
metabolic changes in preterm newborns. 
5.4 Conclusions 
The most significant findings of the thesis are: 
1. Post-HI cerebral energy metabolism is in part controlled by an adenosine-
mediated mechanism. Blocking the adenosine A1 receptor significantly 
diminished the depression of CMRO2 and aEEG typically observed following 
HI. This suppression of cerebral metabolism and electrocortical activity 
following HI is most likely a neuroprotective response. 
 
2. Both NIRS and EEG techniques can be applied simultaneously at the bedside 
of sick newborns, which could help to improve the diagnosis of hypoxic-
ischemic encephalopathy by providing early detection of those infants that 
would benefit from therapy. 
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APPENDIX A 
The contents of this chapter have been adapted from the paper entitled “A near-
infrared spectroscopy study to assess the effects of Indomethacin on cerebral blood 
flow and metabolic rate of oxygen in preterm infants”, in the process of publication in 
the Journal of Pediatric Research by Arora R, Ridha M, et al. 
Responsibilities: Acquisition and analysis of the majority of the data. 
Introduction 
The ductus arteriosus is a vascular structure within the heart that connects the 
aorta to the pulmonary artery. This fetal structure normally closes spontaneously after 
birth. However, in cases where the ductus remains open, known as patent ductus 
arteriosus (PDA), it poses a greater risk for pulmonary edema, hemorrhage and 
decreased perfusion and oxygen delivery to the organs, including the brain [124]. The 
incidence of PDA is inversely correlated to birth weight and gestational age, with 
approximately 40% of infants having a PDA who are below 1000 g or of a gestational 
age less than 28 weeks [125, 126]. 
Treatment of PDA is commonly in the form of a non-steroidal anti-
inflammatory drug (NSAID). Two primarily used ones clinically are: indomethacin 
and ibuprofen [127, 128]. These drugs act similarly by inhibiting the production of 
prostaglandins, constricting the ductus arteriosus, which induces anatomical 
remodeling and ultimately ductal closure. Both drugs have the same efficacies with  
success rates ranging between 60 to 80% [129]. The only notable difference between 
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the two drugs is the physiological side-effect of indomethacin as a vasoconstrictor, 
which has been shown to reduce renal and cerebral perfusion. The latter effect is of 
particular interest considering this is a patient population that is already at high risk of 
brain injury. Thus alterations in cerebral hemodynamics as a consequence of PDA 
treatment remains a concern [128], particularly if these reductions are large enough to 
affect cerebral energy metabolism.  
The objective of the present study was to measure cerebral blood flow (CBF), 
oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen (CMRO2) in 
preterm infants with a hemodynamically significant PDA who have been selected to 
receive treatment with indomethacin. Measurements were obtained prior to and 
immediately following the infusion of the first dose of the drug, which was part of a 
standard three-dose (one dose per day) protocol. CBF was measured with the same 
bolus-tracking NIRS technique using the light-absorbing dye indocyanine green 
(ICG) as described in chapter 1 and 2.  
Method 
Preterm infants (GA< 30 weeks) with hemodynamically significant PDA 
(diagnosed based on clinical indices) were enrolled in the study after obtaining 
informed and written parental consent. All NIRS data were collected with a 
continuous-wave, broadband (600-980 nm) system using two fiber-optic bundles, one 
for light emission and the other for detection [66]. The ends of the fiber bundles were 
held 3.5 cm apart using a custom-built holder that was strapped to the infant’s head to 
position the probes over the frontoparietal region. Measurements of CMRO2, CBF 
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and OEF were determined using the same second derivative spectroscopy technique 
[130] described in Chapter 1 (Sections 1.7 and 1.8).  
Pharmacological treatment of PDA followed the standard indomethacin 
dosage schedule consisting of three doses of 0.2mg/kg, each separated by 24 hours, 
infused intravenously over 30 min. Two NIRS data sets were acquired on the first day 
of treatment, one approximately 5 min prior to the start of drug infusion and the other 
immediately at the end of 30 min infusion. The acquisition period for each ICG run 
was approximately 80 s. The tissue and arterial ICG concentration curves were 
acquired simultaneously by NIRS and the DDG, respectively.  
Results 
Complete data sets (i.e., both NIRS and DDG data before and after first 
treatment dose) were obtained from 8 infants. Figure 1 shows the individual pre- and 
post-treatment values of CBF, CBV, OEF, and CMRO2. A general reduction in CBF 
and CBV was observed as expected due to the known vasoconstricting effects of 
indomethacin. A concurrent increase in OEF was found while CMRO2 displayed no 
significant change. These observations were confirmed by the mean pre- and post-
treatment values given in Table 1. Indomethacin caused a significant decrease in CBF 
of 18% (p<0.025) and in CBV of 17% (p<0.02). There was a significant increase in 
OEF of 29% (p<0.025), but the drug has no overall effect on CMRO2. The PDA was 
closed in all eight cases after the three-dose regimen of indomethacin. 
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Table 1: Clinical parameters and near-infrared spectroscopy measurements before and 
after indomethacin infusion 
Parameter Pre Post 
MAP (mm Hg) 36.9 ± 2.7 38.7± 2.8 
EtCO2  
(mm Hg) 
56.1 ± 2.4 56.0 ± 2.2 
pH 7.28 ± 0.02 7.25 ± 0.01 
Heart Rate 
(beats/min) 
152 ± 4 156 ± 3 
SaO2 (%) 93.6 ± 1.9 93.0 ± 2.0 
CBF  
(ml·100g−1·min−1) 
12.9 ± 1.3 10.6 ± 0.9* 
CBV  
(mL·100 g−1) 
2.05 ± 0.12 1.69 ± 0.09* 
OEF 0.28 ± 0.03 0.36 ± 0.03* 
CMRO2 
(ml O2·100 
g−1·min−1) 
0.59 ± 0.06 0.65 ± 0.07 
Values are mean ± SE (n = 8). MAP: mean arterial blood pressure, EtCO2: end-tidal 
carbon dioxide tension, CBF, cerebral blood flow; CBV, cerebral blood volume; 
[HHb], tissue concentration of deoxy-hemoglobin; OEF, oxygen extraction fraction; 
CMRO2, cerebral metabolic rate of oxygen 
*Significant change with treatment (p < 0.05). 
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Figure 1.  Individual values of pre and post single indomethacin treatment of PDA 
for (a) cerebral blood flow (CBF), (b) cerebral blood volume (CBV), (c) oxygen 
extraction fraction (OEF), and (d) the cerebral metabolic rate of oxygen (CMRO2) (n 
= 8, 0.2 mg/kg). Data from each patient are represented by the same symbol and grey-
scaled line in all graphs. 
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Discussion 
The principle finding of this study was that, despite the significant reductions 
in CBF and CBV caused by a 30-min infusion of indomethacin, there was no change 
in CMRO2. In general, this finding was expected considering that under normal 
conditions CMRO2 should remain stable during relatively moderate reductions in 
CBF due to a compensatory increase in OEF. In this study the approximate 20% 
reduction in CBF was accompanied by a statistically significant increase in OEF of 
29% under indomethacin. It is only when the reduction in CBF is sufficient to impede 
the supply of oxygen to the brain that CMRO2 is expected to be affected [131]. These 
results suggest that, even at this very early age, the cerebral oxygen supply is 
sufficient to accommodate moderate variations in cerebral perfusion. To the best of 
our knowledge this study is the first to report quantitative measurements of CBF and 
CMRO2 in infants obtained using ICG as a contrast agent. These results suggest that 
this methodology could be used for beside assessments with other clinical conditions 
that have the potential to affect cerebral hemodynamics and energy metabolism.  
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